Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

BBIO - BridgeBio Pharma, Inc.


31.57
-0.660   -2.091%

Share volume: 3,266,247
Last Updated: 03-07-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.03%

PREVIOUS CLOSE
CHG
CHG%

$32.23
-0.66
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
30%
Profitability 15%
Dept financing 25%
Liquidity 58%
Performance 40%
Company vs Stock growth
vs
Performance
5 Days
-2.05%
1 Month
1.45%
3 Months
8.94%
6 Months
12.79%
1 Year
9.09%
2 Year
117.27%
Key data
Stock price
$31.57
P/E Ratio 
0.00
DAY RANGE
$31.22 - $32.64
EPS 
-$2.88
52 WEEK RANGE
$21.62 - $39.47
52 WEEK CHANGE
$10.00
MARKET CAP 
5.186 B
YIELD 
N/A
SHARES OUTSTANDING 
188.033 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
1.09
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$3,534,803
AVERAGE 30 VOLUME 
$3,649,588
Company detail
CEO: Neil Kumar
Region: US
Website: bridgebio.com
Employees: 400
IPO year: 2019
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a stabilizer of transthyretin, or TTR.

Recent news